Retatrutide & GLP-1 Side Effects: What the Trials Report

GLP-1 and multi-receptor agonists are among the most closely studied compound classes in current metabolic research, and the adverse-event profiles recorded in their clinical trials are published in detail.

This page summarises what that published literature reports, and what the peptides often named alongside this class are separately studied for. It is not a protocol, a recommendation, or medical advice.

What the trials report

In the published Phase-2 and Phase-3 programmes for retatrutide and related incretin-class compounds, the adverse events investigators recorded most frequently were gastrointestinal — nausea, vomiting, diarrhoea and constipation. Trial reports describe them as dose-dependent, most frequent during the escalation phase, and generally mild to moderate. Body-composition sub-analyses of rapid-change trials have also reported reductions in lean mass alongside fat mass.

How the trial protocols were structured

The published protocols for this class escalated the administered amount gradually across many weeks rather than beginning at the highest level studied. Investigators have linked that design to the dose-dependence of the events above. This records how the studies were run — it is not a schedule and not a recommendation.

BPC-157 in the literature

BPC-157 is a synthetic pentadecapeptide studied in animal models for effects on gastrointestinal tissue and mucosal integrity. That body of work is separate from the incretin literature: no controlled study has examined it in relation to the adverse events of GLP-1-class compounds.

Growth-hormone secretagogues in the literature

CJC-1295, ipamorelin and tesamorelin are studied as growth-hormone secretagogues, and the published work on them concerns growth-hormone axis signalling and body-composition endpoints within their own trial contexts. None has been studied in combination with an incretin-class compound.

NAD+ and SS-31 in the literature

NAD+ is a coenzyme central to cellular redox reactions and to sirtuin, PARP and CD38 activity. SS-31 (elamipretide) is a mitochondria-targeted peptide studied for effects on mitochondrial output and oxidative stress.

Both are researched in mitochondrial and cellular-energetics contexts distinct from incretin pharmacology, and neither has been studied in combination with this compound class.

Material quality comes first

Whatever a research programme covers, the input has to be documented. Every RetaNord lot is tested by an independent laboratory — HPLC for purity and mass spectrometry for identity — and ships with a lot-specific Certificate of Analysis. Read the CoA.